Legacy Healthcare Announces Positive Top-Line Results from Phase 2/3 Trial of Coacillium cutaneous solution, the first drug for children and adolescents with Moderate and Severe Alopecia Areata

/PRNewswire/ -- Legacy Healthcare, a clinical-stage biopharmaceutical company today announced positive results from the RAAINBOW phase 2/3 randomized...

Related Keywords

Switzerland ,Swiss ,Saad Harti ,Treatment In Development ,National Alopecia Areata Foundation ,Meets Primary Endpoint ,Scalp Hair Regrowth ,Key Secondary ,Coacillium During ,Treatment Period Continue ,Improve After Treatment ,Only Treatment ,Moderate Form ,Alopecia Tool ,Chief Executive Officer ,Alopecia Areata ,Pediatric Alopecia ,Legacy Healthcare ,